1. Market Research
  2. > Biotechnology Market Trends
  3. > Gastrointestinal Symptoms Partnering 2010-2015

Gastrointestinal Symptoms Partnering 2010-2015

  • March 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

The Gastrointestinal Symptoms Partnering 2010-2015 report provides understanding and access to the gastrointestinal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in gastrointestinal symptoms partnering deals
Top gastrointestinal symptoms deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Gastrointestinal Symptoms Partnering 2010-2015 provides understanding and access to the gastrointestinal symptoms partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of gastrointestinal symptoms partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastrointestinal symptoms technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 35 links to online copies of actual gastrointestinal symptoms deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of gastrointestinal symptoms partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gastrointestinal symptoms technologies and products.

Report scope

Gastrointestinal Symptoms Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to gastrointestinal symptoms trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in gastrointestinal symptoms dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 80 gastrointestinal symptoms deals
The leading gastrointestinal symptoms deals by value since 2010

In Gastrointestinal Symptoms Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Gastrointestinal Symptoms Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gastrointestinal symptoms partnering

2.1. Introduction
2.2. Gastrointestinal symptoms partnering over the years
2.3. Gastrointestinal symptoms partnering by deal type
2.4. Gastrointestinal symptoms partnering industry sector
2.5. Gastrointestinal symptoms partnering by stage of development
2.6. Gastrointestinal symptoms partnering by technology type

Chapter 3 - Average deal terms for gastrointestinal symptoms

3.1 Introduction
3.2 Average deal terms for gastrointestinal symptoms
3.3 Gastrointestinal symptoms headline values with median calculation
3.4 Gastrointestinal symptoms upfront values with median calculation
3.5 Gastrointestinal symptoms milestone values with median calculation
3.6 Gastrointestinal symptoms royalty rates with median calculation

Chapter 4 - Active gastrointestinal symptoms dealmakers

4.1. Introduction
4.2 Most active gastrointestinal symptoms dealmakers
4.3. Top gastrointestinal symptoms deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Gastrointestinal symptoms dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Gastrointestinal symptoms partnering since 2010
Figure 2: Gastrointestinal symptoms dealmaking activity- 2010 to 2015
Figure 3: Gastrointestinal symptoms partnering by deal type since 2010
Figure 4: Gastrointestinal symptoms partnering by industry sector since 2010
Figure 5: Gastrointestinal symptoms partnering by stage of development since 2010
Figure 6: Gastrointestinal symptoms partnering by technology type since 2010
Figure 7: Gastrointestinal symptoms deals with a headline value
Figure 8: Gastrointestinal symptoms deals with upfront payment values
Figure 9: Gastrointestinal symptoms deals with milestone payments
Figure 10: Gastrointestinal symptoms deals with royalty rates, %
Figure 11: Top gastrointestinal symptoms deals by value since 2010
Figure 12: Big pharma - top 50 - gastrointestinal symptoms deals 2010 to 2015
Figure 13: Big pharma gastrointestinal symptoms deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - gastrointestinal symptoms deals 2010 to 2015
Figure 15: Big biotech gastrointestinal symptoms deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Bundle

Cancer Bundle

  • $ 24 225
  • Industry report
  • January 2016
  • by TriMark Publications

The Cancer Reports Bundle includes the following TriMark Publications reports at a 15% discount off the individual reports being purchased separately: - Biomarker Technology Platforms for Cance ...

2016-2020 Global Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

2016-2020 Global Molecular Diagnostics and NAT Market: Supplier Shares and Market Segment Forecasts by Country

  • $ 9 850
  • Industry report
  • March 2016
  • by Venture Planning Group

This report provides the following data: Geographic Coverage:-          France-          Germany-          Italy-          Japan-          Spain-          ...

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024

  • $ 9 495
  • Industry report
  • January 2016
  • by Global Data

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.